Earnings call: Ultragenyx reports strong Q2 revenue, raises guidance - Investing.com

Retrieved on: 2024-08-04 18:38:57

Tags for this article:

Ultragenyx

Emil Kakkis

Ultragenyx Pharmaceutical Inc

Joshua Higa

Click the tags to see associated articles and topics

Earnings call: Ultragenyx reports strong Q2 revenue, raises guidance - Investing.com. View article details on hiswai:

Summary

The article details Ultragenyx's recent financial and clinical advancements and includes clarity from the Q2 2024 earnings call led by CEO Emil Kakkis and other executives. Key pipeline drugs, such as GTX-102 for Angelman syndrome, and revenue highlights were also discussed. Joshua Higa of Hawaii participated in the call, aligning with business updates from Ultragenyx. Tags directly relate to insights on Ultragenyx’s work and people involved, while the key concept 'Hawaii' ties to one participant, Joshua Higa.

Article found on: www.investing.com

View Original Article